JP2021515806A5 - - Google Patents
Info
- Publication number
- JP2021515806A5 JP2021515806A5 JP2020568847A JP2020568847A JP2021515806A5 JP 2021515806 A5 JP2021515806 A5 JP 2021515806A5 JP 2020568847 A JP2020568847 A JP 2020568847A JP 2020568847 A JP2020568847 A JP 2020568847A JP 2021515806 A5 JP2021515806 A5 JP 2021515806A5
- Authority
- JP
- Japan
- Prior art keywords
- binding
- antigen
- binding protein
- protein according
- triple
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637470P | 2018-03-02 | 2018-03-02 | |
| US62/637,470 | 2018-03-02 | ||
| PCT/EP2019/055207 WO2019166650A1 (en) | 2018-03-02 | 2019-03-01 | Trispecific antigen binding proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021515806A JP2021515806A (ja) | 2021-06-24 |
| JP2021515806A5 true JP2021515806A5 (cg-RX-API-DMAC7.html) | 2022-03-09 |
Family
ID=65802034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568847A Pending JP2021515806A (ja) | 2018-03-02 | 2019-03-01 | 三重特異性抗原結合タンパク質 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200062858A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3759146A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021515806A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210028140A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112119099A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019228128A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3089230A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020009116A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019166650A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| KR102530742B1 (ko) | 2016-05-20 | 2023-05-09 | 하푼 테라퓨틱스, 인크. | 단일 도메인 혈청 알부민 결합 단백질 |
| CA3078969A1 (en) | 2017-10-13 | 2019-04-18 | Harpoon Therapeutics, Inc. | Trispecific proteins and methods of use |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN119306844A (zh) | 2018-09-25 | 2025-01-14 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| EP3816185A1 (en) * | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
| JP7461078B2 (ja) | 2019-11-08 | 2024-04-03 | ナノテンパー・テクノロジーズ・ゲーエムベーハー | 溶液中の粒子の特徴付け |
| JP7369297B2 (ja) | 2019-12-17 | 2023-10-25 | ファイザー・インク | Cd47、pd-l1に特異的な抗体、およびその使用 |
| US20230406955A1 (en) * | 2020-10-22 | 2023-12-21 | Janux Therapeutics, Inc. | Antibodies targeting her2 and cd3 and uses thereof |
| CN114853897B (zh) * | 2021-04-15 | 2024-01-26 | 北京大学深圳研究生院 | 抗cd19/cd22/cd3三特异性抗体及用途 |
| CA3220878A1 (en) * | 2021-06-03 | 2022-12-08 | Harpoon Therapeutics, Inc. | Bcma targeting trispecific proteins and methods of use |
| CN118201961A (zh) * | 2021-09-16 | 2024-06-14 | Gt生物制药公司 | Pd-l1靶向融合蛋白及其使用方法 |
| CN114371282B (zh) * | 2021-12-30 | 2025-07-11 | 上海药明生物技术有限公司 | 一种评估抗原沉默效应对抗体药效影响的方法及其应用 |
| EP4754149A1 (en) * | 2023-07-29 | 2026-06-10 | Shanghai Kaijin Biotechnology , Ltd | Modified type e multi-specific antibodies |
| WO2025109119A1 (en) | 2023-11-22 | 2025-05-30 | Priothera Sas | Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| EP1049787B1 (en) * | 1998-01-23 | 2004-11-24 | Vlaams Interuniversitair Instituut voor Biotechnologie | Multipurpose antibody derivatives |
| CA2326389C (en) | 1998-04-21 | 2007-01-23 | Micromet Gesellschaft Fur Biomedizinische Forschung Mbh | Novel cd19xcd3 specific polypeptides and uses thereof |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| CN102421801B (zh) | 2009-03-10 | 2016-03-16 | 比奥根Ma公司 | 抗-bcma抗体 |
| EP3974453A3 (en) | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| JP6400470B2 (ja) * | 2011-05-16 | 2018-10-03 | ジェネロン(シャンハイ)コーポレイション リミテッド | 多重特異性Fab融合タンパク質および使用法 |
| KR101870555B1 (ko) | 2011-08-23 | 2018-06-22 | 로슈 글리카트 아게 | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Bcmaに対する抗体の選択のための方法 |
| SG11201702401RA (en) * | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| HK1245171A1 (zh) | 2014-11-26 | 2018-08-24 | Xencor, Inc. | 结合cd3和cd38的异二聚体抗体 |
| US10383929B2 (en) | 2014-12-12 | 2019-08-20 | Bluebird Bio, Inc. | BCMA chimeric antigen receptors |
| WO2016115274A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| EP3165536A1 (en) * | 2015-11-09 | 2017-05-10 | Ludwig-Maximilians-Universität München | Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition |
| EP3390454B1 (en) | 2015-12-17 | 2026-02-04 | University of Maryland, Baltimore County | A recombinant bi-specific polypeptide for coordinately activating tumor-reactive t-cells and neutralizing immune suppression |
| US20190031785A1 (en) * | 2016-01-13 | 2019-01-31 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| UA126657C2 (uk) | 2016-02-03 | 2023-01-11 | Емджен Рісерч (Мюнік) Ґмбг | ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font> |
| EP4086285A1 (en) | 2016-02-25 | 2022-11-09 | Cell Medica Switzerland AG | Binding members to pd-l1 |
| US11291721B2 (en) * | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| EP3443006B1 (en) * | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| EP3458481A4 (en) | 2016-05-18 | 2020-07-29 | Mayo Foundation for Medical Education and Research | TARGETING PD-L1 ON TUMOR CELLS |
| HRP20251020T1 (hr) | 2016-05-20 | 2025-10-24 | Harpoon Therapeutics, Inc. | Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3 |
| EP3252078A1 (en) * | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| PL3896091T3 (pl) | 2016-08-10 | 2024-04-29 | Legend Biotech Ireland Limited | Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania |
| WO2018071777A1 (en) | 2016-10-14 | 2018-04-19 | Harpoon Therapeutics, Inc. | Innate immune cell trispecific binding proteins and methods of use |
| US11124577B2 (en) * | 2016-11-02 | 2021-09-21 | Engmab Sàrl | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
| WO2019005637A2 (en) * | 2017-06-25 | 2019-01-03 | Systimmune, Inc. | MULTIPECIFIC ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF |
-
2019
- 2019-03-01 WO PCT/EP2019/055207 patent/WO2019166650A1/en not_active Ceased
- 2019-03-01 KR KR1020207028030A patent/KR20210028140A/ko not_active Ceased
- 2019-03-01 JP JP2020568847A patent/JP2021515806A/ja active Pending
- 2019-03-01 CN CN201980016065.6A patent/CN112119099A/zh active Pending
- 2019-03-01 EP EP19711257.6A patent/EP3759146A1/en not_active Withdrawn
- 2019-03-01 MX MX2020009116A patent/MX2020009116A/es unknown
- 2019-03-01 AU AU2019228128A patent/AU2019228128A1/en not_active Abandoned
- 2019-03-01 CA CA3089230A patent/CA3089230A1/en active Pending
- 2019-08-05 US US16/532,295 patent/US20200062858A1/en not_active Abandoned
- 2019-10-04 US US16/593,704 patent/US20200024358A1/en not_active Abandoned